Kender Richard N 4

What Happened

• Richard N. Kender, Interim Chief Executive Officer of Seres Therapeutics, was granted a derivative equity award for 50,000 shares on 2026-07-08. The grant is reported with a $0.00 acquisition price (derivative security), i.e., an equity award/option rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-08; Form 4 filed: 2026-07-10.
• Security/amount: 50,000 derivative shares granted; reported acquisition price $0.00.
• Vesting/exercise: Footnote (F1) states the option vests and becomes exercisable in 36 equal monthly installments beginning March 2, 2026.
• Filing timeliness: Filing date is 2026-07-10 for a transaction dated 2026-07-08; no late filing flag reported in the filing.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Transaction code: A = Award/Grant.

Context

• This was a grant of a derivative award (an option-like award that vests over time), which is standard for executive compensation; it does not represent an immediate market purchase or sale. The award vests monthly over three years before becoming fully exercisable per the footnote.